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Abstract
Aspergillosis is acquired by inhalation of spores of Aspergillus, a ubiquitous species in the
environment. In normal hosts, spore inhalation rarely causes lung disease.
Pulmonary aspergillosis covers a wide spectrum of clinical syndromes depending on the interaction
between Aspergillus and the host (immune-status, prior bronchopulmonary disease). It runs the
gamut from invasive aspergillosis to Aspergillus bronchitis and colonization.
Invasive aspergillosis occurs in severely immunocompromised patients, typically with neutropenia.
Chronic pulmonary aspergillosis affects patients with chronic structural lung disease such as
chronic obstructive pulmonary disease, mycobacterial lung disease, but without significant
immunocompromise. Aspergillus bronchitis affects patients with bronchial disease such as
bronchiectasis. Allergic bronchopulmonary aspergillosis affects patients with bronchial asthma or
cystic fibrosis, and is due to an allergic response to Aspergillus.
In this review of literature, we discuss the pulmonary manifestations of Aspergillus infection, its
diagnosis and treatments.
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Introduction
Aspergillosis is a disease caused by fungi of the genus
Aspergillus principally A. fumigatus, and less commonly A.
flavus, A. terreus, and A. niger. The name Aspergillus is derived
from its resemblance to the sporulating head of Aspergillus and
the aspergillum/aspergill used to sprinkle holy water (from latin
aspergere: to sprinkle.) Aspergilli are filamentous saprophytic
molds ubiquitous in nature that grow in soil, decaying
vegetation, and water. Direct examination of Aspergillus within
tissue reveals septated hyphae which dichotomously branch at
45° as shown in Figure 1.
While Aspergillus can involve a variety of organ systems,
including the respiratory (lung, sinuses), central nervous, ocular,
gastrointestinal/hepatic and renal systems causing significant
morbidity and mortality [1, 2]. This review of literature will focus
on the pulmonary manifestations of Aspergillus infections.
Aspergillus causes a spectrum of pulmonary diseases (presented
in Table 1) determined by the interplay between the pathogen
Aspergillus, underlying lung disease and the host immunity
[3-7]. On one end of the spectrum, invasive pulmonary
aspergillosis (IPA) predominantly affects patients with severe
immune dysfunction, while chronic pulmonary aspergillosis
(CPA) affects patients with underlying lung disease but with
an absence of, or mild immune dysfunction. Acute community-

acquired Aspergillus pneumonia occurs in patients without
significant immune deficits and normal lungs. Aspergillus
bronchitis is a chronic bronchitis that is mostly seen in nonimmunocompromised patients with bronchiectasis or cystic
fibrosis. Allergic bronchopulmonary aspergillosis is due to an
allergic response to inhaled Aspergillus in asthmatics.
Invasive Pulmonary Aspergillosis
Acute invasive pulmonary aspergillosis (IPA) is a rapidly
progressive infection that occurs in highly immunocompromised
patients and carries a mortality upwards of 50 to 80%. [8, 9]
The classic risk factor for IPA is neutropenia and the likelihood
of IPA depends on the duration and severity of neutropenia.
Histologically, IPA in neutropenic hosts shows angioinvasion
(Figure 2), while IPA in non-neutropenic patients does not
usually demonstrate angioinvasion and occurs in a wide range of
conditions: allogeneic hematopoietic stem-cell transplantation
after neutrophil recovery, solid organ transplantation, advanced
AIDS, chronic granulomatous disease, and critically-ill ICU
patients [10]. The most common risk factors for these patients is
the use of chronic corticosteroid therapy.
IPA has been increasingly diagnosed in non-neutropenic ICU
patients who have non-specific risk factors such as sepsis,
chronic obstructive pulmonary disease (COPD), steroid therapy,
multiple antibiotic treatments, and hepatic and/or renal failure.
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Table 1. Spectrum of Diseases Caused by Aspergillus adapted from Denning et al [3]. (HSCT = Hematopoietic stem-cell transplant; CGD = Chronic
granulomatous disease).

Aspergillosis syndromes

Immune Status

Underlying Lung Disease

Invasive Pulmonary Aspergillosis (IPA)

Immunocompromised host

None

Tracheobronchial Aspergillosis (TBA)

a. Prolonged and profound
neutropenia
b. Non-neutropenic:
Corticosteroids, HIV/AIDS,
HSCT recipient, solid organ
transplant, CGD
Immunocompromised host

Lung transplant

(AIDS, post-transplant)
Chronic Pulmonary Aspergillosis (CPA)

Non-immunocompromised host

Emphysema, previous
cavitary tuberculosis

Aspergillus bronchitis

Non-immunocompromised host

Bronchiectasis

Acute Community-Acquired Aspergillus
Pneumonia

Non-immunocompromised host

Normal lungs/post-influenza

Allergic Bronchoulmonary Aspergillosis
(ABPA)

Non-immunocompromised host

Asthma, cystic fibrosis

Chronic cavitary CPA, fibrosing CPA,
aspergilloma, and nodule(s)

Hypersensitivity to Aspergillus

Figure 1. A photomicrograph of lung tissue on autopsy showing
Aspergillus hyphae with acute angle branching on H&E stain.

The diagnosis of IPA is based on the criteria mentioned in Table
2. Histopathologic visualization of fungal elements alone is not
sensitive enough to diagnose invasive aspergillosis and should
be accompanied by immunostains, cultures and where available,
nucleic acid amplification tests (NAAT) [11, 12[. Assays for
PCR and NAAT are not commercially available yet and require
submission of samples to research or reference laboratories
that have validated assays. The galactomannan assay is a
fairly specific and sensitive test for the diagnosis of invasive
pulmonary aspergillosis. Galactomannan is found in the cell
wall of Aspergillus species and the assay can be performed in
serum, BAL and pleural fluid, although the sensitivity is higher
when performed in BAL fluid than in serum. Galactomannan
assay results are always used in combination with culture and
histopathology results. The sensitivity of the assay increases
with repeated testing (one week apart) and has the highest
sensitivity among patients with hematological malignancies or
post-hematopoietic stem cell transplantation [13].
False positive serum and BAL galactomannan assays can be
caused by several beta-lactam antibiotics including piperacillintazobactam and carbapenem [14]. Galactomannan is also found
in the cell walls of histoplasma capsulatum and fusarium
spp. The concurrent use of caspofungin has been associated
with a higher sensitivity of the galactomannan assay likely
due to the increase in galactomannan levels released from cell
wall breakdown. In addition to the galactomannan, serum 1,3
beta-D-glucan test may be helpful, keeping in mind the crossreactivity with pseudomonas can yield false positive results [13].

Figure 2. A photomicrograph of lung tissue on autopsy showing
angioinvasion by Aspergillus on H&E stain.

Sepsis probably causes a state of ‘immunoparalysis’ and steroids
cause an immunodeficient state that promotes the occurrence
of IPA.

Treatment of IPA
Voriconazole is the recommended primary therapy for IPA
based on a randomized trial that compared voriconazole with
amphotericin B deoxycholate and showed improved survival
with voriconazole [16]. Voriconazole can be given intravenously
or orally. Alternative primary therapies are liposomal
amphotericin B and isavuconazonium. Recently, the FDA has
approved isavuconazonium (a pro-drug of isavuconazole) for
intravenous and oral treatment of IPA[17]. The recommendation
was based on a randomized trial of isavuconazonium vs
voriconazole. All-cause mortality and overall response rates
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Table 2. Diagnostic criteria for invasive pulmonary aspergillosis per the European Organization for the Research and Treatment of Cancer (EORTC) and
the Mycosis Study Group [15].

Proven Invasive Pulmonary
Aspergillosis
¥ Sterile biopsy showing hyphae
branching at 45° (morphologically
suggestive of Aspergillus) with
evidence of associated tissue
damage
OR
¥ Aspergillus on culture of lung biopsy
specimens

Probable Invasive Pulmonary Aspergillosis Possible Invasive Pulmonary
Aspergillosis
Clinical criteria (one of the following):
Clinical criteria (one of the following):
¥ Recent history of neutropenia (absolute
¥ Recent history of neutropenia
neutrophil count < 500 cells)
(absolute neutrophil count < 500 cells)
¥ Allogeneic stem-cell transplant recipient ¥ Allogeneic stem-cell transplant
¥ Prolonged corticosteroid exposure (mean recipient
¥ Prolonged corticosteroid exposure
dose > 0/3mg/kg/day of prednisone
(mean dose > 0/3mg/kg/day of
equivalent for 13 weeks)
prednisone equivalent for 13 weeks)
¥ Therapy with known T-cell
¥ Therapy with known T-cell
immunosuppressive agents (e.g.
immunosuppressive agents (e.g.
Cyclosporine, tacrolimus, etc.)
Cyclosporine, tacrolimus, etc.)
¥ Hereditary severe immunodeficiency
¥ Hereditary severe immunodeficiency
AND
AND
Radiologic criteria on CT (one of the
Radiologic criteria on CT (one of the
following):
¥ Well-circumscribed, dense lesions ± halo following):
¥ Well-circumscribed, dense lesions ±
sign
halo sign
¥ Air-crescent sign
¥ Air-crescent sign
¥ Cavitary lesion
¥ Cavitary lesion
AND
Mycological criteria (one of the following):
(Serial testing of beta-D-glucan and
¥ Cytology, culture or microscopy of
respiratory sample (BAL, bronchial brush) galactomannan may improve sensitivity
and specificity)
showing fungal elements or growing
Aspergillus
¥ Detection of antigen or cell-wall
components (e.g. Galactomannan in
serum, plasma or BAL)

were similar in both groups.
Patients who do not respond to monotherapy are considered for
combination antifungal therapy usually with an echinocandin
in addition to voriconazole or liposomal amphotericin B.
The treatment of IPA should be continued for a minimum
of 6 to 12 weeks, dependent on the duration and severity of
immunosuppression and the clinical response to therapy [18].
Tracheobronchial Aspergillosis (TBA)
Tracheobronchial aspergillosis is a unique feature of IPA,
representing isolated tracheobronchial invasion. Predisposing
factors for TBA are similar to those for IPA, however it has
been mainly described in lung transplantation recipients, and
patients with AIDS. The diagnosis requires bronchoscopy. TBA
has been classified into 3 forms (19). Obstructive TBA manifests
as thick mucus plugs loaded with Aspergillus spp. without
obvious bronchial inflammation. Pseudomembranous TBA is
characterized by extensive involvement of the tracheobronchial
tree with a membranous slough overlying the mucosa containing
Aspergillus as shown in Figure 3.
Ulcerative TBA is a focal process usually found at the suture
line of the tracheobronchial anastomosis in lung transplant
recipients. The diagnosis of TBA is usually made by the
characteristic findings on bronchoscopy (Figure 4) combined
with microbiological and pathological analysis of the respiratory
specimens obtained during bronchoscopy.
Treatment of TBA
Similar to IPA, voriconazole or lipid formulation of amphotericin
B is used. Bronchoscopic debridement of airway lesions and
minimization of immunosuppression when feasible are also
considered [20]. In lung transplant recipients with anastomotic
TBA, adjunctive inhaled amphotericin B is recommended. The
duration of antifungal therapy is at least 3 months, or until TBA
has completely resolved.
Neutropenic Fever in Patients with Cancer
Neutropenic patients can be classified as high-risk or low-risk
[21]. Patients with any of the following are considered high-risk
if they have:

Figure 3. Pseudomembranous tracheobronchial aspergillosis in an
immunocompromised patient. a: A cross-section of the trachea at the level
of the carina showing pseudomembranous tracheobronchial aspergillosis.
b: Photomicrograph at low-power showing the pseudomembrane of the
same patient on H&E stain. c: High-power photomicrograph displaying
Aspergillus hyphae in the pseudomembrane on H&E stain.

a.
b.

profound neutropenia (ANC < 100 cells/m3), anticipated
to be prolonged (> 7 days), and
the presence of medical comorbidities: hemodynamic
instability,
oral
mucositis
causing
dysphagia,
gastrointestinal symptoms (abdominal pain, nausea,
vomiting or diarrhea), new-onset neurologic changes,
pneumonia, intravascular catheter infections [21].
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Figure 5. A schematic to illustrate the different forms of chronic pulmonary
aspergillosis, in particular the overlap that is often seen – reproduced from
Denning et al with permission [22].

Figure 4. Bronchoscopic view of the carina showing the
appearance of ulcerative tracheobronchial aspergillosis in a
lung transplant recipient.

High-risk patients who have received intensive cytotoxic
chemotherapy are at risk for “invasive” fungal infections; yeasts
(primarily Candida species) and molds (primarily Aspergillus).
They typically cause persistent or recurrent fever in patients
with profound (≤ 100 cells/mm3) and prolonged (> 10-15 days)
neutropenia. Fever may be the only sign in the early stages of
fungal infections.
The Infectious Diseases Society of America (IDSA) recommends
empiric antifungal therapy for high-risk neutropenia in patients
with persistent or recurrent fever after 4-7 days of empirical
broad spectrum antibiotic therapy [21].
Chronic Pulmonary Aspergillosis (CPA)
There are a multitude of chronic forms of CPA that may overlap
as illustrated in Figure 5. The progression of CPA is slow
with a duration of at least 3 months. It affects patients with
underlying chronic lung conditions, namely tuberculous and
non-tuberculous mycobacterial infections, COPD, bullous lung
disease, ABPA, asthma, pulmonary fibrocystic sarcoidosis, lung
radiation, rheumatoid arthritis, and ankylosing spondylitis [3].
The key diagnostic test for CPA is the detection of IgG to
Aspergillus (or the less sensitive serum Aspergillus precipitins).
Positive anti-Aspergillus antibodies differentiate infected
patients from colonized patients, with a positive predictive value
of 100% for infection. Positive PCR, culture of Aspergillus, or
galactomannan in respiratory samples provide supportive
evidence. The diagnostic criteria for CPA are outlined in Figure
6.
The most common form of CPA is chronic cavitary pulmonary
aspergillosis which occurs in non-immunocompromised

Clinical Criteria:
¥ Chronic pulmonary or systemic symptoms (duration >
3 months) including at least one of the following
symptoms: weight loss, productive cough or
hemoptysis.
¥ No overt immunocompromised conditions (e.g.
hematological malignancy, neutropenia, organ
transplantation, chronic granulomatous disease)
AND
Radiological Criteria:
¥ Cavitary pulmonary lesions with evidence of paracavitary infiltrates, new cavitary formation, or
expansion of cavitary size over time.
AND
Laboratory Criteria:
¥ Either positive result of serum precipitins or IgG to
Aspergillus or isolation of Aspergillus species from
pulmonary or pleural cavity.
¥ Elevated levels of inflammatory markers (C-reactive
protein, erythrocyte sedimentation rate).
¥ Exclusion of other pulmonary pathogens, by results of
appropriate cultures and serological tests, that are
associated with similar disease presentation,
including mycobacteria and endemic fungi.
Figure 6. An outline of the diagnostic criteria as by Denning et al [23]. All
criteria must be met to diagnose chronic pulmonary aspergillosis.

patients with lung disease. When untreated, it may progress to
chronic fibrosing pulmonary aspergillosis as shown in Figure
7. Less common forms of CPA are Aspergillus nodule(s) and
single aspergilloma shown in Figure 8.
Sub-acute invasive aspergillosis also known as chronic
necrotizing pulmonary aspergillosis. It develops over 4-12
weeks, usually affects mildly immunocompromised patients
and manifests with variable radiological features including
cavitation, nodules, progressive consolidation with ‘abscess
formation’.
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Treatment of CPA
1.
Treatment of chronic cavitary and fibrosing aspergillosis
Patients with CPA and with pulmonary symptoms
including progressive loss of lung function or radiographic
progression should be treated with a minimum of 6
months of antifungal therapy [18]. Oral Itraconazole and
voriconazole are the preferred oral antifungal agents;
posaconazole is an alternative therapy for those with
adverse effects or clinical failure. Patients with subacute
invasive aspergillosis should be managed as invasive
aspergillosis.
2. Treatment of simple aspergilloma
Surgical resection is a definitive treatment for patients with
adequate pulmonary function. Intracavitary instillation
of amphotericin B is an effective short-term treatment
to control severe hemoptysis [24]. Mild to moderate
hemoptysis can be controlled with tranexamic acid that
inhibits fibrinolysis of clots. Catheter embolization of
the bronchial arteries may be a lifesaving procedure for
severe hemoptysis, either as a temporizing measure before
surgery or as a definitive treatment.
3. Treatment of Aspergillus nodule
A single Aspergillus nodule that has been completely
excised does not need antifungal treatment if the patient
is immunocompetent. In immunocompromised patients,
an oral azole such as oral itraconazole is indicated [3]. In
a patient with multiple nodules who undergoes surgical
excision of a single nodule, azole therapy is recommended
and these patients require radiographic follow up with
chest CT after excision of a single nodule. If the residual
nodules are progressive, continued azole therapy is
indicated and a repeat biopsy should be considered to rule
out other etiologies [22].

Figure 7. Radiographic appearance of fibrosing CPA on axial (a) CT
images with coronal (b) reconstruction showing extensive parenchymal
destruction with cavitation, bronchiectasis and an aspergilloma in the
right-upper lobe.

Figure 8. Single aspergilloma (fungal ball) inside a chronic tuberculous
cavity overlapping with subacute invasive aspergillosis.

Acute Community-Acquired Aspergillus Pneumonia
There appear to be 3 different presentations of community
acquired Aspergillus pneumonia:
1.
massive exposures to airborne Aspergillus spores that
overwhelm the immunity of the lung to fight infection
(‘mulch pneumonitis’)
2. lower levels of exposure following influenza infection
3. patients with COPD and those on chronic systemic
corticosteroid therapy
Chest imaging shows a diffuse miliary pattern in cases of
massive exposure, or unilateral upper-lobe cavitary disease.
Aspergillosis may occur in the setting of severe influenza
infections even among immunocompetent hosts and carries a
mortality rate of almost 50% [25]. Diagnosis requires a high
level of suspicion. Aspergillus can be isolated from optimal
respiratory tract specimens (bronchoalveolar lavage and
bronchial brushings) and galactomannan should be detectable
in the bronchoalveolar lavage (BAL) fluid.
Prompt therapy with voriconazole is recommended given the
high mortality rates [26].
Aspergillus bronchitis
Aspergillus bronchitis is a chronic superficial Aspergillus
infection of the bronchial tree in a non-immunocompromised
patient, usually with bronchiectasis or cystic fibrosis. If
the patient has significant immunocompromise (recent
chemotherapy, transplantation, or AIDS) the term IA
tracheobronchitis should be applied. Dr. Denning’s group
proposed the following criteria for the diagnosis of chronic
Aspergillus bronchitis [27].
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Table 3. A table comparing the diagnostic criteria for ABPA by the ABPA Working Group and those proposed by Agarwal et al [29]. (COPD: chronic
obstructive pulmonary disease; kUA: kilounit of antibody; mgA: milligram of antibody; ABPA: Allergic bronchopulmonary Aspergillosis; Ig: immunoglobulin.)
ABPA Working Group Criteria
Predisposing conditions:
 Bronchial asthma and cystic fibrosis
Essential criteria:
 Serum A. fumigatus specific IgE levels > 0.35 kUA/L
or positive type I Aspergillus skin test
AND
 Elevated serum total IgE levels > 1000 IU/ml (an IgE
value <1000 IU/ml may be acceptable if all other
criteria are met, especially if the serum A.
fumigatus specific IgG level > 27 mgA/L).
Additional criteria (two of three must be met):
 Presence of precipitating (or IgG) antibodies against
A. fumigatus in serum
OR
 Thoracic imaging findings consistent with ABPA
o Transient abnormalities: nodules, consolidation,
mucoid impaction, hyper-attenuating mucus,
fleeting opacities, toothpaste/gloved-finger
opacities, or tram-track sign
o Permanent abnormalities: parallel lines, ring
shadows, bronchiectasis, pleuropulmonary
fibrosis
OR
 Historical or current peripheral blood eosinophil
count > 500 cells/µL.

Criteria Proposed by Agarwal et al
Predisposing conditions:
 Bronchial asthma, cystic fibrosis, COPD, post-tuberculous fibrocavitary disease
Essential criteria:
 Serum A. fumigatus specific IgE levels > 0.35 kUA/L (a positive type I Aspergillus skin test
may be considered as a criterion in place of serum A. fumigatus specific IgE levels only if
the latter test is not available)
AND
 Elevated serum total IgE levels > 1000 IU/ml (an IgE value <1000 IU/ml may be acceptable
if all other criteria are met, especially if the serum A. fumigatus specific IgG level >27
mgA/L).
Additional criteria (two of three must be met):
 Serum A. fumigatus IgG level > 27 mgA/L
OR
 Thoracic imaging findings consistent with ABPA
o Transient abnormalities: nodules, consolidation, mucoid impaction, hyper-attenuating
mucus, fleeting opacities, toothpaste/gloved-finger opacities
o Permanent abnormalities: parallel lines, ring shadows, bronchiectasis,
pleuropulmonary fibrosis
OR
 Historical or current peripheral blood eosinophil count > 500 cells/µL.

Essential criteria
1.
Microbiology: Demonstration of Aspergillus in the
airways at least twice (sputum culture or PCR positive for
Aspergillus)
2. Chronic (>4 weeks) pulmonary symptoms: Chronic
productive cough, tenacious mucus production, recurrent
bronchitis exacerbations with poor response to antibiotics
and possible systemic symptoms.
3. No significant immune system deficiency.

Bronchial asthma
Aspergillus fumigatus specific IgE levels > 0.35
kUA/L
Total IgE > 500 IU/mL
Eosinophil count > 500 cells/µL
Aspergillus fumigatus IgG > 27 mgA/L
High-resolution chest CT

Supportive Criteria
4. Serology: Aspergillus antibody detectable in serum.
5. Bronchoscopy findings: Thick tenacious mucus with
bronchial plugging, bronchial erythema, or ulceration.
Superficial invasion of mucosa by Aspergillus hyphae.
6. Response to therapy: Good response to an eight-week
course of antifungal therapy.
Treatment of Aspergillus bronchitis
Oral azole therapy (itraconazole, voriconazole, posaconazole)
for 4 months is effective in the majority of patients, however,
relapse risk is about 50% and these patients may need long-term
therapy [27].
Allergic Bronchopulmonary Aspergillosis
ABPA is a pulmonary disorder caused by hypersensitivity to
Aspergillus fumigatus that complicates the course of patients
with asthma and cystic fibrosis. It presents with different
clinical and radiological manifestations such as refractory
asthma, recurrent fleeting pulmonary infiltrates with or without
bronchiectasis. ABPA should be suspected in all patients with
asthma and cystic fibrosis regardless of the severity or the level
of disease control. A working group of ‘ABPA in asthmatics’
formed by the International Society of Human and Animal
Mycology (ISHAM) convened an expert group that proposed
new criteria for ABPA in 2013 [28]. Subsequently, Agarwal
et al have recently proposed new criteria outlined in Table 3
[29]. Comparing the ABPA working group criteria to the criteria
proposed by Agarwal et al, the proposed criteria include a larger
array of lung disease (COPD, post-tuberculous fibrocavitary
disease) and identifies a specific A. fumigatus IgG level. The
diagnostic algorithm for ABPA is outlined in Figure 9.

High-attenuation mucus

Bronchiectasis

Normal

ABPA with highattenuation mucus

ABPA with
bronchiectasis

Serologic ABPA

Figure 9. Suggested protocol for the diagnosis of allergic
bronchopulmonary aspergillosis (ABPA) adapted from Agarwal et al [29].

Treatment of ABPA
ABPA has distinct stages of progression from an acute infection
(stage 1) to advanced ABPA (stage 6) as listed in Table 4. The
treatment of ABPA has been described by Agarwal et al [29],
highlighted in the flowchart shown in Figure 10. Primary
treatment of ABPA involves corticosteroids for asthma attacks
associated with ABPA. The most frequently used schedule is
the low-dose steroid regimen (prednisone 0.5mg/kg/day) for
2 weeks followed by 0.5/mg/kg every other day for 8 weeks,
then tapered by 5mg every 2 weeks for a total duration of 3 to
5 months. Alternative treatments describe oral Itraconazole
200mg twice daily for 16 weeks or longer. Itraconazole has
been shown to decrease the number of exacerbations requiring
steroids with improved lung function and exercise tolerance.
[30, 31] Itraconazole can eliminate Aspergillus in the airways
and can theoretically reduce the allergic responses in ABPA.
The aim of the MIPA trial (Monotherapy of Itraconazole Versus
Prednisolone in Allergic Bronchopulmonary Aspergillosis;
clinicaltrials.gov ID: NCT01321827), a prospective randomized
controlled trial that is currently underway, is to evaluate the
efficacy and safety of itraconazole monotherapy in patients with
ABPA.
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Table 4. The treatment stages of ABPA adapted from Agarwal et al [29].

Stage Definition
0
Asymptomatic
1

Acute ABPA

2

Response

3

Exacerbation

4

Remission

5

Treatmentdependent

6

Advanced ABPA

Features
No previous diagnosis of ABPA
Fulfills criteria for ABPA
Controlled asthma per GINA guidelines
No previous diagnosis of ABPA
Fulfills criteria for ABPA
Uncontrolled asthma or symptoms consistent with ABPA
Clinical and/or radiographic improvement
AND
Decline in IgE ≥ 25% of baseline at 8 weeks
Clinical and/or radiographic worsening
AND
Increase in IgE ≥ 50% from baseline established during response/remission
Sustained clinical and radiographic improvement
AND
IgE levels persisting at or below baseline (or increase by < 50) for ≥ 6 months off treatment
Systemic glucocorticoids require for control of asthma while the ABPA activity is controlled (as
indicated by IgE levels and thoracic imaging
OR
2 or more exacerbations within 6 months of stopping therapy
OR
Worsening of clinical and/or radiographic condition with rise in IgE levels on tapering steroids
Extensive bronchiectasis due to ABPS on chest imaging
AND
Complications such as cor pulmonale or chronic respiratory failure

References

Acute stage ABPA
(stage 1)

1.

Treat with 4 months of glucocorticoids

Follow-up chest radiograph, spirometry, total
lgE levels
Response
(stage 2)

Off steroids
for 6 months

Remission
(stage 4)

Exacerbation
(stage 3)
Steroids for 4 months + itraconazole for 6
months
Treatment-dependent
(stage 5)
Long-term therapy: azoles, low-dose
glucocorticoids, methylprednisolone pulses,
nebulized amphotericin, omalizumab

Figure 10. A flowchart illustrating the treatment and response algorithm
adapted from Agarwal et al [29].

Conclusions
The different clinical syndromes caused by Aspergillus can be
considered as a continuous spectrum of disease resulting from
the interplay of Aspergillus, host immunity and underlying
lung disease. The spectrum runs from invasive pulmonary
aspergillosis to Aspergillus bronchitis. One form of aspergillosis
may evolve from one form into another depending of the degree
of immunity of the host. Prompt diagnosis and treatment with
appropriate antifungals are essential for improved outcomes.
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